Literature DB >> 27084120

Normal tissue considerations and dose-volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer.

Cathy Fleming1, Daniel N Cagney2, Serena O'Keeffe1, Sinead M Brennan2, John G Armstrong2, Brendan McClean3.   

Abstract

Hypofractionated radiation therapy (RT) regimes in non-small cell lung cancer (NSCLC) have become increasingly popular with a number of international trials currently underway. The majority of the dose-volume-constraints (DVCs) published in the literature refer to conventional 2Gy per fraction deliveries. Here relevant organs-at-risk (OARs) are identified and available dose-volume constraint data discussed and summarised for moderately hypofractionated NSCLC regimes. The OARs examined include lung, brachial plexus, heart, oesophagus, airway and spinal cord. Where available the toxicity rates are also reported with all data summarised tabulated to aid its use in the clinic.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  DVCs; Dose–volume constraints; Hypofractionated; NSCLC; Toxicity

Mesh:

Year:  2016        PMID: 27084120     DOI: 10.1016/j.radonc.2016.03.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer.

Authors:  Louise Turtle; Neeraj Bhalla; Andrew Willett; Robert Biggar; Jonathan Leadbetter; Georgios Georgiou; James M Wilson; Sindu Vivekanandan; Maria A Hawkins; Michael Brada; John D Fenwick
Journal:  Radiat Oncol       Date:  2021-06-03       Impact factor: 3.481

2.  The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.

Authors:  S Vivekanandan; D B Landau; N Counsell; D R Warren; A Khwanda; S D Rosen; E Parsons; Y Ngai; L Farrelly; L Hughes; M A Hawkins; J D Fenwick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-27       Impact factor: 7.038

3.  Genetic variants of SP-D confer susceptibility to radiation pneumonitis in lung cancer patients undergoing thoracic radiation therapy.

Authors:  Li Xu; Junhong Jiang; Yunming Li; Ling Zhang; Zhihui Li; Jing Xian; Chaoyang Jiang; Yong Diao; Xiaomei Su; Hongyu Xu; Yue Zhang; Tao Zhang; Zhenzhou Yang; Bangxian Tan; Hua Li
Journal:  Cancer Med       Date:  2019-03-21       Impact factor: 4.452

4.  Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic.

Authors:  Sameera Kumar; Steven Chmura; Clifford Robinson; Steven H Lin; Shirish M Gadgeel; Jessica Donington; Josephine Feliciano; Thomas E Stinchcombe; Maria Werner-Wasik; Martin J Edelman; Drew Moghanaki
Journal:  J Thorac Oncol       Date:  2020-04-28       Impact factor: 15.609

5.  Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.

Authors:  Carsten Nieder; Kristian S Imingen; Bård Mannsåker; Rosalba Yobuta; Ellinor Haukland
Journal:  Radiat Oncol       Date:  2020-05-01       Impact factor: 3.481

6.  Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival.

Authors:  Carsten Nieder; Kristian S Imingen; Ellinor Haukland
Journal:  J Clin Med Res       Date:  2021-03-19

7.  Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials.

Authors:  Gustavo Arruda Viani; Andre Guimaraes Gouveia; Fabio Ynoe Moraes
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

8.  Chromosomal Aberrations in Blood Lymphocytes as Predictors of Respiratory Function After Stereotactic Lung Irradiation.

Authors:  Zsuzsa S Kocsis; Gyöngyi Farkas; András Bajcsay; Márta Kun-Gazda; József Lövey; Gyula Ostoros; Tamás Pócza; András Herein; Katalin Ladányi; Gábor Székely; Zsolt Markóczy; Zoltán Takácsi-Nagy; Csaba Polgár; Zsolt Juranyi
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

9.  Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer.

Authors:  Yue-E Liu; Xiao-Ying Xue; Rui Zhang; Xue-Ji Chen; Yu-Xia Ding; Chao-Xing Liu; Yue-Liang Qin; Wei-Qian Li; Xiao-Cang Ren; Qiang Lin
Journal:  BMJ Open       Date:  2020-10-23       Impact factor: 2.692

10.  Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study.

Authors:  Juliette Degens; D De Ruysscher; Ruud Houben; Bastiaan Kietselaer; Gerben Bootsma; Lizza Hendriks; Ellen Huijbers; Annemie Schols; Anne-Marie C Dingemans
Journal:  BMJ Open       Date:  2020-09-28       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.